Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Business updates and financial results announced August 10, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $243.7M, including $222.4M Attruby sales versus $110.6M total revenue in Q2 2025
- Attruby momentum supported by treatment-naïve adoption and real-world data showing 37% fewer cardiovascular events versus tafamidis
- Three pipeline NDAs entered FDA review, with BBP-418 PDUFA November 27, 2026 and encaleret PDUFA May 8, 2027
- Cash and marketable securities $720.2M at June 30, excluding $1B preferred equity financing closed July 1
- Net loss narrowed to $152.2M, or $0.78 per share, from $181.9M, or $0.95, in Q2 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.